Instil Bio, Inc.

NasdaqCM TIL

Instil Bio, Inc. Price to Book Ratio (P/B) on January 14, 2025: 0.65

Instil Bio, Inc. Price to Book Ratio (P/B) is 0.65 on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Instil Bio, Inc. 52-week high Price to Book Ratio (P/B) is 2.56 on September 13, 2024, which is 293.52% above the current Price to Book Ratio (P/B).
Instil Bio, Inc. 52-week low Price to Book Ratio (P/B) is 0.26 on June 26, 2024, which is -59.60% below the current Price to Book Ratio (P/B).
Instil Bio, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 0.67.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: TIL

Instil Bio, Inc.

CEO	Mr. Bronson Crouch
IPO Date	March 19, 2021
Location	United States
Headquarters	3963 Maple Avenue
Employees	49
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Key trends

Past 5 years